文献速递前列腺癌

前列腺癌家族史与英国遗传性前列腺癌研究中的生存结局

Family History of Prostate Cancer and Survival Outcomes in the UK Genetic Prostate Cancer Study.
PubMed 文献 · Eur Urol · 2022-12-16

英国遗传性前列腺癌研究为纵向、多机构、观察性研究,自1992年起收集基线及随访临床数据,分析16340例前列腺癌患者中家族史强度与总生存及前列腺癌特异性生存的关系。结果显示家族史越强,全因及前列腺癌特异性死亡风险越低,且随受累亲属数量和亲缘 closeness 增加而更明显。作者认为死亡降低可能几乎完全源于对疾病认知的提高,提示筛查和认知项目的重要性。

要点

  • 至少有一位一级亲属的患者全因死亡风险低于无家族史者(HR=0.82,95%CI 0.75-0.89)。
  • 家族史越强,全因及前列腺癌特异性死亡风险越低(数量 p-trend<0.001,亲缘 closeness p-trend<0.001)。
  • 作者认为死亡降低可能几乎完全源于对疾病认知的提高,提示筛查和认知项目的重要性。

核心结论

  • 基于对亲属癌症类型和时间的调查,死亡降低可能几乎完全源于对疾病认知的提高。
  • 本研究为临床医生根据家族风险指导患者及其亲属提供信息,并显示筛查和认知项目的重要性,这些项目可能改善有家族史男性的生存。

研究设计与样本

  • 英国遗传性前列腺癌研究为纵向、多机构、观察性研究,自1992年起收集基线及随访临床数据。
  • 研究纳入16340例男性,按患前列腺癌及遗传相关癌症(乳腺、卵巢、结直肠)亲属的 degree 和数量分析总生存及前列腺癌特异性生存。

主要发现

  • 家族史越强,全因及前列腺癌特异性死亡风险越低,且随受累亲属数量增加(p-trend<0.001)和亲缘 closeness 增加(p-trend<0.001)而更明显。
  • 至少有一位一级亲属的患者全因死亡风险低于无家族史者(HR=0.82,95%CI 0.75-0.89)。

临床怎么用

  • 作者认为本研究为临床医生根据家族风险指导患者及其亲属提供信息,并显示筛查和认知项目的重要性。

局限性

  • 人群主要为欧洲血统,可能造成代表性和外推性问题。
  • 缺少吸烟等死亡流行病学危险因素及合并症的数据。
  • 对家庭成员诊断的回忆可能影响未确认病例的家族史分类。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A family history (FH) of prostate cancer (PrCa) is associated with an increased likelihood of PrCa diagnosis. Conflicting evidence exists regarding familial PrCa and clinical outcomes among PrCa patients, including all-cause mortality/overall survival (OS), PrCa-specific survival (PCSS), aggressive histology, and stage at diagnosis. OBJECTIVE: To determine how the number, degree, and age of a PrCa patient's affected relatives are associated with OS and PCSS of those already diagnosed with PrCa. DESIGN, SETTING, AND PARTICIPANTS: The UK Genetic Prostate Cancer Study is a longitudinal, multi-institutional, observational study collecting baseline and follow-up clinical data since 1992. We examined OS and PCSS in 16340 men by degree and number of relatives with prostate and genetically related cancers (breast, ovarian, and colorectal). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary outcome was all-cause mortality among PrCa patients. The risk of death with respect to FH was assessed by calculating hazard ratios from Cox proportional hazard regression models, adjusting for relevant factors. RESULTS AND LIMITATIONS: A stronger FH was inversely associated with the risk of all-cause and PrCa-specific mortality. This association was greater in those with an increasing number (p-trend < 0.001) and increasing closeness (p-trend < 0.001) of the diagnosed relatives. Patients with at least one first-degree relative were at a lower risk of all-cause mortality than those with no FH (hazard ratio = 0.82 [95% confidence interval 0.75-0.89]). The population is largely of European ancestry, and this may cause an issue with representation and generalisation. Data are missing on epidemiological risk factors for death such as smoking and on comorbidities. Recall of family members' diagnoses may affect the classification of FH in unconfirmed cases. CONCLUSIONS: Based on the investigation of the type and timing of relatives' cancers, it is likely that reductions in mortality are due almost completely to a greater awareness of the disease. This study provides information for clinicians guiding patients and their relatives based on their familial risk. It shows the importance of screening and awareness programmes, which are likely to improve survival among men with an FH. PATIENT SUMMARY: We were interested in how a family history of prostate cancer affects survival in prostate cancer patients. We studied 16340 patients, categorised them according to the strength of their family history, and found that the stronger their family history, the better they did in terms of overall survival. We looked at the type and timing of patients' diagnoses compared with those of their relatives and found that this effect is likely to be explained by awareness, which indicates the importance of screening and awareness programmes.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Brook MN, Ní Raghallaigh H, Govindasami K, et al. Family History of Prostate Cancer and Survival Outcomes in the UK Genetic Prostate Cancer Study. Eur Urol. 2022. PMID: 36528478. doi:10.1016/j.eururo.2022.11.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。